- Home
- KRUS vs GHRS Comparison
KRUS vs GHRS Comparison
Compare KRUS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRUS | GHRS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 849.5M | 1.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRUS | GHRS |
|---|---|---|
| Price | $72.04 | $16.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $81.50 | $32.00 |
| AVG Volume (30 Days) | 378.9K | ★ 673.8K |
| Earning Date | 01-07-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $291,762,000.00 | N/A |
| Revenue This Year | $19.23 | N/A |
| Revenue Next Year | $20.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.31 | N/A |
| 52 Week Low | $40.03 | $7.98 |
| 52 Week High | $95.98 | $20.50 |
Technical Indicators
Market Signals| Indicator | KRUS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 58.40 |
| Support Level | $70.48 | $15.48 |
| Resistance Level | $77.00 | $17.33 |
| Average True Range (ATR) | 4.77 | 1.64 |
| MACD | 0.93 | 0.15 |
| Stochastic Oscillator | 79.19 | 60.65 |
Price Performance
Historical ComparisonAbout KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.